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Abstract
Introduction: Craniopharyngiomas (CP) are rare epithelial tumors of the sellar region. Two subtypes,
adamantinomatous (adaCP) and papillary CP (papCP), were previously identified based on histomorphological and
epidemiological aspects. Recent data indicates that both variants are defined by specific genetic alterations, and
influenced by distinct molecular pathways and particular origins. The fact that CP is an uncommon tumor entity
renders studies on large cohorts difficult and exceptional. In order to achieve further insights distinguishing CP
variants, we conducted whole genome methylation (450 k array) and microarray-based gene expression studies in
addition to CTNNB1 and BRAF mutation analysis using a comprehensive cohort of 80 adaCP and 35 papCP.
Results: BRAFV600E mutations were solely found in the papCP subgroup and were not detectable in adaCP
samples. In contrast, CTNNB1 mutations were exclusively detected in adaCP. The methylome fingerprints assigned
DNA specimens to entity-specific groups (papCP (n = 18); adaCP (n = 25)) matching perfectly with histology-based
diagnosis, suggesting that they represent truly distinct biological entities. However, we were not able to detect
within the adaCP group (including 11 pediatric and 14 adult cases) a significant difference in methylation signature
by age. Integrative comparison of the papCP with the adaCP group based on differential gene expression and
methylation revealed a distinct upregulation of Wnt- and SHH signaling pathway genes in adaCP.
Conclusions: AdaCP and papCP thus represent distinct tumor subtypes that harbor mutually exclusive gene
mutations and methylation patterns, further reflected in differences in gene expression. This study demonstrates
that DNA methylation analyses are an additional method to classify CP into subtypes, and implicates a role of
epigenetic mechanisms in the genesis of the respective CP variants. Detection of tumor-specific signaling pathway
activation enables the possibility of target-oriented intervention.
Keywords: Craniopharyngiomas, BRAF V600E, Illumina, β-Catenin, Wnt, SHH
* Correspondence: annett.hoelsken@uk-erlangen.de
†Equal contributors
1Institute of Neuropathology, Friedrich-Alexander University
Erlangen-Nürnberg (FAU), Schwabachanlage 6, D-91054 Erlangen, Germany
Full list of author information is available at the end of the article
© 2016 Hölsken et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Hölsken et al. Acta Neuropathologica Communications  (2016) 4:20 
DOI 10.1186/s40478-016-0287-6
Introduction
Craniopharyngiomas (CPs) are defined as histologically
benign epithelial tumors of the sellar region [27, 34]. Re-
ported world-wide incidence rates of 1.86 (1.60–2.14)
new cases per million per year for all ages and 2.14
(1.53–2.92) for children under 15 years demonstrate that
they represent rare lesions [15, 37, 39]. Although the
growth pattern of CP is often locally aggressive and
treatment is challenging, histological signs of malignancy
are missing-thus defining them as grade I tumors ac-
cording to the World Health Organization (WHO) clas-
sification [31]. There are two different subtypes of CP,
papillary (papCP) and adamantinomatous (adaCP). Al-
though clear histomorphological differences between
both variants exist, a correct diagnosis is sometimes dif-
ficult to obtain, especially in small and/or fragmented
specimens. Furthermore, the existence of mixed forms
and the cell of origin of these tumors are areas of on-
going scientific debate [40, 41].
The papCP variant occurs almost exclusively in adults, at
an age of 40–55 years [12]. They are composed of compact,
monomorphic sheets of well-differentiated squamous epi-
thelium and typically lack regressive changes like choles-
terol clefts, calcifications, wet keratin and inflammation.
Ciliated epithelium and PAS+ goblet cells are sometimes
encountered, and histological morphology resembles that
of Rathke’s cleft cysts with squamous metaplasia.
The adaCP variant is the most common non-
neuroepithelial intracerebral neoplasm in children, ac-
counting for 5–11 % of intracranial tumors in this age
group [19, 42]. A second peak occurs in adulthood be-
tween 50–74 years [7]. Histopathological hallmarks of
adaCP are the formation of differentiated epithelium dis-
posed in cords, lobules, nodular whorls and irregular tra-
beculae bordered by palisaded columnar epithelium.
Cystic cavities containing cell debris and fibrosis are lined
by flattened epithelium. Pale nodules containing anucleate
“ghost cells”/”wet keratin”, large areas of regressive
changes i.e. inflammation and calcifications are represen-
tative. Further characteristic features of adaCP are finger-
like tumor protrusions and the formation of a tumor-
specific cellular environment in the surrounding brain tis-
sue [8, 22]. This is accompanied by serious endocrino-
logical and visual disturbances and significant long term
morbidity and mortality rates, and makes treatment quite
a challenge [26, 36].
Recent data has provided important insights into the
molecular pathogenesis and origin of CP, and may provide
distinguishing features for both subtypes associated with
new molecular drug targets. Today it is common know-
ledge that the Wnt signaling pathway is strongly impli-
cated in the pathogenesis of adaCP. Genetic analyses have
shown that up to 95 % of the tumors harbor activating
mutations in exon 3 of the CTNNB1 gene encoding β-
catenin [5, 10, 28, 45]. Genetic alterations within the deg-
radation targeting box of β-catenin lead to activation of
the pathway in adaCP, indicated by aberrant nuclear accu-
mulation of the protein and respective Wnt target gene
activation [24]. This is described to be exclusive for adaCP
[5, 30] and aberrant (nuclear) immunohistochemical stain-
ing for β-catenin in whirl-like cell clusters and single cells
represent the most reliable marker for adaCP in the differ-
ential diagnosis of space occupying lesions in the sellar
region [21]. Activated Wnt signaling influences tumor cell
migration and the tumor initiating strength of this alter-
ation was recently confirmed in vivo [18, 22, 48]. Further-
more, it was shown that EGFR- and SHH signaling
pathways are also up-regulated in adaCP and associated
with tumor cell migration [1, 2, 20, 23].
The molecular background of papCP initiation was
largely unknown until exome sequencing studies re-
vealed BRAF mutations (BRAF p.Val600Glu) in up to
95 % of these tumors [5]. This result was confirmed in
smaller series of samples, where BRAF V600E mutations
could be reliably detected by immunohistochemistry [29,
30, 44]. Interestingly, Brastianos and colleagues postu-
lated that CTNNB1 and BRAF mutations were exclusive
and clonal in each CP subtype, and they detected no
other recurrent mutations or genomic aberrations in ei-
ther subtype [5, 30]. In contrast, Larkin et al. claimed
that BRAF mutations may coexist with CTNNB1 muta-
tions in adamantinomatous tumors [30].
BRAF mutations were described in several other neo-
plasms and potent drugs have already shown a robust
clinical response in melanomas, hairy cell leukemias, as
well as brain tumors with BRAF p.Val600Glu such as
pilocytic astrocytoma, pleomorphic xanthoastrocytoma
and ganglioglioma [13, 14, 16, 33, 43]. Recently, two case
reports of BRAF inhibitor treatment (Vemurafenib and
Dabrafenib in combination with Trametinib) in patients
with residual or recurrent papCP after surgery have been
published, showing favorable short-term effects. How-
ever, the Vemurafenib-treated tumor displayed tumor re-
growth after a drug holiday, indicating that further long-
term studies are necessary [3, 4].
In order to verify and strengthen the above summa-
rized molecular data and to reveal distinctive molecular
characteristics that facilitate the diagnosis of both CP
subtypes, we obtained CTNNB1 and BRAF mutational
analysis as well as array-based gene expression and
methylation profiling in one of the largest cohorts of hu-
man CP tissue samples published to date.
Materials and methods
Patient cohort
Surgical specimens from patients with CP were retrieved
from the archive of the Department of Neuropathology
at the University Hospital of Erlangen (n = 107) and
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from the department of Neuropathology at the Univer-
sity of Heidelberg (n = 8). The investigated samples con-
tained 35 papillary CP (papCP; 20 female and 15 male
patients; mean age = 46.3 years) and 80 adamantinoma-
tous CP (adaCP) from 79 different patients (40 female
and 39 male patients; mean age = 35.7 years). The adaCP
samples included 25 childhood (mean age of patients
≤16 years = 8.5 years) and 55 adult (mean age =
48.2 years) tumor samples. One adult patient (marked
by an asterisk in Table 1) had a relapse 14 years after the
first surgery and both tumor samples were selected for
mutational analysis. Methylation analysis was performed
from 18 papCP and 25 adaCP. AdaCP consisted of 11
childhood and 14 adulthood tumors in order to analyze
whether there are differences in the methylation profiles
in respective age groups. Gene expression analysis was
performed for 10 papCP and 18 adaCP for which good
quality RNA was available.
Each tumor sample was classified according to World
Health Organization (WHO) guidelines using haematoxy-
lin and eosin as well as immunohistochemical stainings
e.g. pan-cytokeratin (KL-1) and β-catenin. We included
one CP (pap11) where subtype specification was initially
difficult to obtain by histological and immunohistochemi-
cal criteria. A declaration of consent of each patient is
available for all specimens for further scientific investiga-
tion, approved by the local ethics committee of the
University of Erlangen. Procedures were conducted in ac-
cordance with the Declaration of Helsinki.
Immunohistochemistry
Surgical samples were prepared as previously described
[9]. The slides were stained using a Ventana BenchMark
ultraimmunostainer (Ventana, Tuscon, AZ, USA) and
the following antibodies: monoclonal mouse-anti-β-ca-
tenin (1:800, Clone 14, BD Biosciences, Franklin Lakes,
New Jersey); monoclonal antibody that selectively recog-
nizes the BRAF V600E mutant epitope (BRAF V600E-
specific clone VE1, Ventana, USA). The staining protocol
included pretreatment with cell conditioner 1 (pH 8,4) for
64 min, incubation with antibody at 36 °C for 16 minutes,
primary antibody detection using the ultraView Universal
DAB Detection Kit (Ventana), followed by counterstaining
with hematoxylin for 4 minutes. Validation of the VE1
antibody has been previously reported in detail [11].
DNA and RNA preparation
We selected representative native tumor samples and
paraffin embedded tissue for mutational analysis and
confirmed vital tumor content microscopically in each
case. DNA was extracted using the DNeasy tissue kit
and the QIAamp DNA micro kit purchased from Qiagen
(Hilden, Germany). Pooled DNA obtained from periph-
eral blood leukocytes of healthy persons were extracted
with the Blood DNA kit (Qiagen) according to the man-
ufacturer’s instructions and served as wild type controls.
RNA from snap frozen tissue was isolated with the
RNeasy extraction kit (Qiagen) followed by subsequent
digestion with RNase-free DNase I and purification via
RNeasy columns (Qiagen).
DNA and RNA concentration was determined using
the Qubit® dsDNA HS Assay Kit or RNA Assay Kit (Life
Technologies, Eugene, USA).
Mutational analysis
Genomic DNA of exon 3 of CTNNB1 (encoding β-
catenin) and exon 15 of BRAF was amplified for single
strand conformation polymorphism (SSCP) analysis using
the following primer pairs: CTNNB1_for: GATTTGATG
GAGTTGGACATGG; CTNNB1_rev: TGTTCTTGAGT
GAAGGACTGAG (218 bp); or CTNNB1_for: AGTTGG
ACATGGCCATGGAA; CTNNB1_rev: ACATCCTCTTC
CTCAGGATT (145 bp); BRAF_for: TCCTTTACTTACT
ACACCTCA; BRAF_rev: AGTAACTCAGCAGCATCT
CA (204 bp). PCR reactions were performed in a total vol-
ume of 10 μl with at least 10 ng genomic DNA. The amp-
lified PCR products were denatured for 10 min at 94 °C.
SSCP electrophoresis of exons and exon fragments was
performed on polyacrylamide gels (14 %) and a bis-
acrylamide/acrylamide ratio of 1:99, with 5 % glycerol in
0.5x TBE at room temperature. The single and double
strands of the PCR products were visualized by silver
staining, as described previously [6]. The shifted bands
were excised from the wet gel, eluted and reamplified. The
purified PCR-products were sent to GATC Biotech AG
(Konstanz, Germany) for DNA sequencing. CTNNB1
mutation analysis was conducted as described in detail
elsewhere [10].
Pyrosequencing
Pyrosequencing of BRAF codon 600 was carried out
with the therascreen® BRAF Pyro Kit (Qiagen, cat.no
971470) on the PyroMark Q24 platform (Qiagen) ac-
cording to manufacturer’s instructions. Pyrograms were
generated and analyzed with the PyroMark Q24 software
(version 2.0.6.). The light signal (in relative light/fluores-
cent units, RLU) generated by the pyrosequencing reac-
tions is proportional to the amount of DNA template
and the number of nucleotides incorporated into a target
DNA strand. Data are displayed in the form of a pyro-
gram, a series of peaks on a graph. The height ratio be-
tween the peaks allows for the estimation of allele
frequencies (in % units). The mutant allele frequency is
the proportion of a particular variant allele among all
allelic copies of a sample. Samples with a mutation fre-
quency greater than the limit of detection (LOD) plus 3 %
units were scored as mutation positive. Evaluation of
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Table 1 Summary of mutational and immunohistochemical analyses
Case Age Sex Mutational analysis Immunohistochemistry
CTNNB1 exon 3 BRAF exon 15 BRAF Pyro VE1 nuclear β-catenin
pap1 37 f wt V600E V600E + neg
pap2 52 m wt V600E - - neg
pap3 19 m wt V600E - - neg
pap4d,e 49 f wt V600E V600E ++ neg
pap5 43 f wt V600E - - neg
pap6 57 f wt V600E - - neg
pap7d,e 42 m wt V600E V600E ++ neg
pap8d 46 f wt V600E - - neg
pap9d,e 58 m wt V600E V600E ++ neg
pap10 40 m wt V600E V600E + neg
pap11b,d,e 38 m wt V600E - - neg
pap12 57 m wt V600E - - neg
pap13d,e 39 m wt V600E V600E ++ neg
pap14 61 f wt V600E - - -
pap15 56 f wt V600E - - neg
pap16d,e 45 m wt V600E - - neg
pap17 62 f wt V600E - - neg
pap18d,e 36 m wt V600E V600E + neg
pap19d,e 40 m wt V600E V600E - neg
pap20d 36 f wt V600E - - neg
pap21e 48 f wt V600E V600E + neg
pap22e 48 f - - V600E ++ neg
pap23e 34 m wt V600E V600E ++ neg
pap24 43 m wt V600E - - neg
pap25 41 f wt V600E - - neg
pap26 47 f wt V600E V600E - neg
pap27 34 f wt V600E - - neg
pap28 74 m wt V600E V600E - neg
pap29a,e 53 f - - - - -
pap30a,e 41 f - - - - -
pap31a,e 51 f wt - V600E - -
pap32a 2 50 m wt - V600E - -
pap33a,e 23 f wt - V600E - -
pap34a,e 69 f wt - V600E - -
pap35a,e 50 f - - V600E - -
ada1 33 m S33C wt - - neg
ada2 26 f S33P wt - - pos
ada3 33 f G34V wt - - pos
ada4 42 m S33A; S33C wt - - pos
ada5 14 f S37Y wt - - pos
ada6d,e 14 m T41I wt - - pos
ada7c 61 f S45P wt - - neg
ada8c 47 f S45P wt - - pos
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Table 1 Summary of mutational and immunohistochemical analyses (Continued)
ada9 2 f T41I wt - - pos
ada10 3 m D32H wt - - pos
ada11d,e 11 m T41I wt wt - pos
ada12 64 f S45F wt - - pos
ada13 77 m S33A wt - - -
ada14 20 m A32F wt - - pos
ada15 49 m G34R wt - - pos
ada16d,e 56 m S33F wt wt - pos
ada17 21 f S33Y wt - - pos
ada18 70 m S33C wt - - pos
ada19d,e 9 f S33C; T41S wt - - pos
ada20 8 m S33C wt - - pos
ada21d,e 15 m T41I wt - - pos
ada22 54 f S33F wt - - pos
ada23 4 f S37F wt - - pos
ada24 52 f G34C wt wt - pos
ada25 51 m G34R wt - - pos
ada26 47 f T41I wt - - pos
ada27 43 f G34V wt - - neg
ada28 48 f T41I wt - - pos
ada29d,e 66 m T41I wt wt - pos
ada30d 11 f T41A wt wt - pos
ada31d,e 7 m G34R wt - - pos
ada32d,e 50 m I35S wt wt - pos
ada33d,e 15 f T41A wt wt - pos
ada34 6 f I35I; S37F wt - - pos
ada35 57 f D32Y wt - - pos
ada36 58 f S33C wt - - pos
ada37d,e 32 m D32V wt - - pos
ada38 28 m D32N wt - - pos
ada39 6 m G34V wt - - pos
ada40 66 f S37C wt - - pos
ada41 48 m S37F wt - - -
ada42 67 m G34R wt - - pos
ada43 3 f S37F wt wt - pos
ada44 47 f S33C wt - - pos
ada45 64 m S33C wt - - pos
ada46e 3 m S33F wt wt - pos
ada47 5 f G34V wt - - pos
ada48d,e 59 m S33C wt wt - pos
ada49 72 m S37V wt - - pos
ada50 4 f D32H wt - - pos
ada51 53 m S33C wt - - -
ada52 45 m T41I wt - - pos
ada53d,e 38 f S33C wt wt - pos
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potential low level mutations (mutation frequency ≥ LOD
and ≤ LOD+ 3 % units) was performed taking into ac-
count histological tumor cell content and VE1 immuno-
histochemical findings.
Gene expression profiling
Affymetrix U133 Plus2.0 expression array data were gen-
erated at the Microarray Department of the University
of Amsterdam, the Netherlands according to manu-
facturer’s instructions. The MAS5.0 algorithm of the
GCOS program (Affymetrix Inc) was used for
normalization and assignment of detection p-values.
Array quality was ensured by inspection of beta-actin
and GAPDH 5′-3′ ratios as well as the percentage of
present calls. Data were further interrogated using the
R2 microarray analysis suite (http://r2.amc.nl). For
this analysis 18 adaCP and 10 papCP samples (Table 1)
were included.
To cluster samples and determine an optimal number
of stable clusters, unsupervised consensus clustering
[35] was applied. Clustering was performed using the
log2 gene expression values of the 5000 most variably
expressed genes as measured by standard deviation.
Within each of the 1000 resampling iterations of the
consensus clustering, a hierarchical clustering using
ward linkage as agglomeration method and euclidean
distance as distance measure was applied. The most
stable clustering for K = 2 clusters was determined by
Table 1 Summary of mutational and immunohistochemical analyses (Continued)
ada54d,e 16 f D32N wt wt - pos
ada55 38 f T41I wt - - pos
ada56d,e 39 m S33C wt wt - pos
ada57 61 f S33C wt - - pos
ada58d,e 58 m S33A wt wt - pos
ada59d,e 45 m 36_37del wt wt - pos
ada60e 48 m D32Y wt - - pos
ada61 28 m S33C wt - - pos
ada62 64 f T41A wt - - -
ada63 53 f S33C wt - - pos
ada64 9 m S33F wt - - pos
ada65 8 f S33C wt - - pos
ada66e 50 f D32H wt wt - pos
ada67 20 f T41I wt - - pos
ada68 50 m S33C wt - - pos
ada69 25 f D32H wt - - pos
ada70d,e 37 m D32H wt wt - pos
ada71 12 f T41I wt wt - pos
ada72 54 m del-85bp wt - - pos
ada73 27 f S33C wt - - pos
ada74 61 f D32F wt - - pos
ada75e 37 m 35-46del wt wt - pos
ada76e 51 m D32Y wt wt - pos
ada77 63 m S33F wt - - pos
ada78e 9 f - - - - pos
ada79e 9 f S33F - wt - pos
ada80a e 9 f T41A - wt - -
Age illustrates time at tumor surgery. Samples were screened for CTNNB1 and BRAF mutation using different standard techniques
VE1 BRAF V600E specific antibody, m male, f female, wt wild type, pos positive, neg negative, Pyro Pyrosequencing
aPatient cohort under study comprising tissue specimens of papillary (pap) and adamantinomatous (ada) craniopharyngiomas (CP), collected from the archives of
the Departments of Neuropathology in Erlangen and Heidelberg
b = unclear CP subtype, − = not analysed, c = samples of one patient with a recurrent tumor after 14 years
dsamples subject to analyses of gene expression using Affymetrix U133 Plus2.0 expression array or e450 k Illumina methylation array
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visually inspecting the resulting consensus matrices and
delta-K criteria.
Methylome profiling
For this analysis DNA from snap frozen tissue (n = 10) or
formalin-fixed tissue (n = 33) with tumor content >60 %
was extracted. The Illumina Infinium HumanMethyla-
tion450 (450 k) array was used to obtain the DNA
methylation status of 482,421 CpG sites (Illumina,
San Diego, USA), according to the manufacturer’s in-
structions at the Genomics and Proteomics Core Facility
of the DKFZ. The methylation level of each CpG site was
represented by beta-values, which ranged from 0
(unmethylated) to 1 (methylated). The following criteria
were applied to filter the data: removal of probes targeting
sex chromosomes, removal of probes containing a single
nucleotide polymorphism (dbSNP132 Common) within
five base pairs of and including the targeted CpG-site
(n = 24,536), and probes not mapping uniquely to the
human reference genome (hg19) allowing for one mis-
match (n = 9993). In total, 438,370 probes were kept for
analysis.
To cluster samples and determine an optimal number
of stable clusters, unsupervised consensus clustering [35]
was applied. Clustering was performed using the beta
values of the 10,000 most variably methylated probes as
measured by median absolute deviation (MAD). Within
each of the 1000 resampling iterations of the consensus
clustering, a hierarchical clustering using ward linkage as
agglomeration method and euclidean distance as distance
measure was applied. The most stable clustering for K = 2
clusters was determined by visually inspecting the result-
ing consensus matrices and delta-K criteria.
To reorder the 10,000 most variable probes for the heat-
map visualization, probes were clustered by agglomerative
hierarchical clustering using the euclidean distance as dis-
tance measure and average linkage as agglomeration
method.
In addition, to apply a different unsupervised method
to reveal groups of samples within the methylation data,
principle component analysis (PCA) was applied to the
same 10,000 probes selected for the clustering, but
transformed to M-values by logit-transformation before
applying PCA.
A scatterplot that shows the samples projected onto
the first two principle components is shown in Fig. 2a.
Differential gene expression and methylation analysis
Ensemble gene annotations (GRCh37.p5) and Affymetrix
probe localizations were obtained from MartView
(http://www.biomart.org). For the integrated analysis
only cases for which both methylation and gene expres-
sion data were available were used (n = 25). The cohort
includes samples of eight papCP and 17 adaCP (Table 1).
CpG sites were mapped to genes by aggregating the
methylation beta values in the range of + − 5 kb of the
transcription start site (TSS) of all protein-coding tran-
scripts by taking the mean of the 25 % most variant
CpG probes measured by MAD. After excluding non-
protein-coding transcripts and genes with no measured
CpG sites in the considered region around the TSS, the
total number of genes was 12,548. T-tests were applied
to identify genes which are differentially methylated or
differentially expressed between adaCP and papCP. To
meet the normality assumption of the t-test, aggregated
beta methylation values were transformed to M-values
by logit-transformation. In addition, to deal with the
multiple testing problem the Bonferroni correction was
applied and genes with a p-value < α/(2×12,548) were
considered significantly, differentially expressed/methyl-
ated. The nominal type one error level to control the
family-wise error rate (FWER) was α = 5 %. In addition,
to find age-dependent differences, 7 childhood and 10
adult adaCP samples were compared by following the
same procedure.
Results
AdaCP and papCP harbor distinctive gene mutations
Mutational analysis of CTNNB1 and BRAF was per-
formed in 110 and 112 human CP tumor samples re-
spectively (Table 1). Genetic alterations within the
CTNNB1 gene were analyzed using SSCP followed by
direct sequencing of divergent bands. We found activat-
ing mutations and small deletions affecting exon 3 of
CTNNB1 exclusively in the group of adaCP. Most of the
identified aberrations directly involved serine or threo-
nine phosphorylation sites of β-catenin, being essential
for its degradation and inhibition [Codon 33 in 28 cases,
followed by codons 41 (n = 16) and 32 (n = 13)]. In ac-
cordance with this, we were able to detect tumor cells
with nuclear β-catenin accumulations in 96 % (72/75) of
the adaCP specimens but in none of the papCP samples
examined. The results are summarized in Table 1.
BRAF mutations were only detectable in papCP (33/33)
but not in the large group of adaCP (0/79) examined in
our series. SSCP analysis displayed shifted bands of vari-
able intensity in all of the analyzed (n = 27) papCP tumor
samples (Fig. 1a). Subsequent Sanger sequencing con-
firmed the presence of BRAF V600E mutation (Fig. 1b)
and additional pyrosequencing of 18 papCP cases revealed
(n = 6) or verified (n = 12) mutations (Fig. 1c, Table 1). In
contrast, we were not able to detect any evidence of a
BRAF V600E mutation in 22 adaCP cases using pyrose-
quencing. One primary and recurrent adaCP tumor sam-
ple from the same patient was available for targeted
genotyping and exhibited the same CTNNB1 mutation
(S45P) but no additional alteration.
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VE1 immunohistochemistry indicated the presence of
mutant BRAF protein in all papCP cases tested (n = 10).
The staining appeared cytoplasmic with a diffuse to
finely granulated, either homogenous or patchy distribu-
tion pattern. Staining intensity ranged from weak (+) to
moderate (++) (Fig. 1d and Table 1). The labeling in
multilayered squamous epithelium was accentuated in
the apical zone and in some cases almost undetectable
in the basal cell layer.
Gene expression analysis confirmed over-activation of
specific markers and important embryonic signaling
pathways in human adaCP
To unravel possible differences in the gene expression
profile of human CP subtypes we performed microarray
analysis of 18 adaCP and 10 papCP samples. Data
analysis revealed significant up-regulation of several dir-
ect targets of the Wnt/β-catenin signaling pathway in
adaCP compared to papCP, including LEF1 and AXIN2
(Additional file 1: Figure S1). Furthermore, important
components of the hedgehog signaling pathway e.g.
GLI2, PTCH1 as well as SHH (Additional file 1: Figure S1)
were also over-expressed specifically in adaCP. Gene
expression data showed increased expression of MAP2
(MAP2), Tenascin C (TNC) and the stem cell marker
CD133 (PROM1) in adaCP (Additional file 1: Figure
S1A). CD44 and Claudin 1 (CLDN1), a recently de-
scribed distinguishing marker for the two variants [47],
are significantly down regulated in adaCP (Additional
file 1: Figure S1). Values of the gene expression analysis
are given in detail for each sample in Additional file 2:
Table S1.
Fig. 1 Detection of BRAF V600E mutation in papCP. SSCP analyses revealed shifted bands (▸) only in papCPs (a). DNA extraction and subsequent
Sanger sequencing confirmed a BRAF V600E mutation (b). Pyrosequencing was utilized in cases with only slight SSCP bands or less available DNA
concentrations. Case pap26 exhibited a low (9.2 %) frequency of BRAFV600E mutation (c). Immunohistochemical staining using a mutation specific
BRAF V600E antibody (clone VE1) revealed a positive staining of pap23 rated with ++ (d). sc = staining control; wt = wild type; NTC = non
template control
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Furthermore, unsupervised consensus clustering of the
gene expression values of the 5000 most variable genes
resulted in two distinct and stable clusters that perfectly
separate adaCP and papCP samples.
DNA methylation profiles differ in adaCP and papCP
We then analyzed the most variably methylated CpG
sites (10,000 genomic loci) in a cohort of 25 adaCP
(11 pediatric and 14 adult cases) and 18 papCP sam-
ples (Table 1). Unsupervised hierarchical clustering of
these loci revealed two distinct and stable methylation
clusters (Fig. 2). Applying PCA to the same CpG sites
revealed comparable results, i.e. Fig. 2a shows a scat-
terplot of the samples projected onto the first two
principle components. As with the clustering result of
the gene expression data, the first cluster contained
only papCP and the second cluster was composed ex-
clusively of adaCP. The histologically unclear case
marked in red grouped clearly to the papCP cluster
(Fig. 2a, b).
It is of note, that integrated methylation and gene ex-
pression analysis revealed significant hypomethylation of
AXIN2 (Wnt pathway) as well as GLI2 and PTCH1
(SHH pathway) associated with high gene expression
within the respective tumors (Fig. 3a, b).
However, comparison of the pediatric and adult cases
of adaCP group revealed no significant difference in the
integrated methylation and gene expression analysis
(Additional file 3: Figure S2).
Discussion
Two different subtypes of craniopharyngiomas (CP) have
to be distinguished according to the current version of
the WHO classification of tumors of the central nervous
system [31]. Both variants, the adamantinomatous CP
(adaCP) and the papillary CP (papCP), differ in their his-
tomorphology, age distribution and clinical course.
Whereas papCP occur almost exclusively in adults,
adaCP have a bimodal age distribution with incidence
peaks in children and adults aged 45–60 years [32]. The
most significant factor associated with recurrence is the
extent of surgical resection which depends on tumor size
and localization. Nowadays there is a trend towards less
radical extirpation in order to avoid hypothalamic injury
[38]. To prevent a higher recurrence rate after incom-
plete surgical resection, additional radiotherapy is widely
used. Histological evidence of brain invasion through
the building of finger-like tumor protrusion, which is
more frequently documented in the adaCP type than in
the papCP type, seems not to correlate with higher re-
currence rates in cases with gross surgical resection [49].
Discrimination of CP variants is often challenging in
only small and/or fragmented surgical specimens, and
the existence of CP with a mixed histological pattern
was specified and promoted in several reports [40, 41].
Newly described molecular markers may help to solve
this problem, and innovative approaches with large
numbers and well characterized tumor samples are re-
quired in order to determine important implications for
the differential diagnosis and treatment of CP. Our re-
sults, obtained in one of the largest cohorts to date, indi-
cate that both variants can clearly be distinguished using
genetic and epigenetic profiling. Targeted genotyping re-
vealed activating mutations and small deletions in exon
Fig. 2 Methylation profiling of CP subtypes. The scatterplot (a)
shows samples projected onto the first two principle components
derived by applying PCA to the most variable 10,000 probes already
selected for the clustering. Pediatric CP are marked with white
circles and adult CP with black circles. Unsupervised consensus
clustering of 450 k methylation data revealed two distinct and
stable clusters corresponding to papCP and adaCP, respectively. The
upper part of the figure shows the consensus matrix (brown) that
displays the stability of the clusters, i.e. in all of the 1, 000 resampling
iterations of the consensus clustering the same samples were assigned
to the same two clusters (b). The lower part of the figure shows a
heatmap of the methylation pattern of the 10,000 most variable CpG
sites used for clustering. Below the heatmap the two clusters resulting
from the consensus clustering of gene expression data is shown.
Furthermore, the distribution of age, BRAF and CTNNB1 mutations
across samples was added. The sample marked with a red dot
represents a case with histologically unsure subtype classification
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3 of CTNNB1 (β-catenin) exclusively in adaCP cases.
Using immunohistochemistry we were able to detect
tumor cells with nuclear β-catenin accumulation only in
the adaCP specimens tested. In contrast, BRAF muta-
tions were detectable in all of the papCP tumor samples.
Results of SSCP analyses could be verified using pyrose-
quencing and VE1 immunohistochemistry, with all mu-
tations being of the hotspot V600E type. Our results are
in line with a previous study published by Brastianos et al.,
showing CTNNB1 alterations in 92–96 % of adaCP and
BRAFV600E mutations in a frequency of 95–100 % of
papCP, depending on the detection method and the
tumor purity [5]. The assumption that both mutations
were mutually exclusive was recently questioned, how-
ever. In a small cohort of adaCP two tumors with
CTNNB1 alterations in codon 41 (T41I) and additional
BRAF V600E mutations were described [30]. To assess
this specific correlation we included 11 adaCP with the
described CTNNB1 gene mutation (codon 41, T41I) in
our analysis. However, we were not able to detect add-
itional alterations in BRAF in any of the adaCP samples
studied. We also analyzed one patient showing a tumor
relapse occurring 14 years after first surgery, but did not
detect additional genomic alterations. Both the primary
tumor and recurrence showed the same CTNNB1 muta-
tion. Our work validates the hypothesis that these muta-
tions are mutually exclusive in the CP subtypes and
represent valuable molecular markers to differentiate
papCP and adaCP. Several other studies have verified the
benefit of CTNNB1 and BRAFV600E in the differential
diagnosis of sellar lesions and we support this statement,
with the caveat that V600E mutations may also occur for
example in sellar pilocytic astrocytomas, and thus sup-
portive histology is also required [21, 29, 44].
Fig. 3 Comparison of adaCP and papCP methylation and gene expression profile. Volcano plot (a) showing the difference in median methylation
of genes between adaCP (n = 17) and papCP (n = 8) samples on the x-axis and the –log10 transformed p-values of the corresponding t-test results
on the y-axis. The volcano plot on the right hand side shows the difference in mean gene expression of genes between adaCP and papCP samples
on the x-axis and corresponding –log10 transformed t-test p-values on the y-axis. Genes significantly differentially methylated and differentially
expressed are marked red. AXIN2, PTCH1 and GLI2, indicated in blue, are significantly hypomethylated and show an increased gene expression in adaCP
samples. (b) Plotting of tumor specific AXIN2, GLI2 and PTCH1 methylation values (beta scale, x-axis) and gene expression values (log2, y-axis) revealed a
significant different clustering of adaCP and papCP subtypes. Corresponding box plots clearly emphasize that there is an inverse correlation between
gene expression and methylation
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The apparent mutual exclusivity of CTNNB1 and
BRAFV600E mutations in the CP variants indicates that
both subtypes have a different molecular origin. This
suggestion is supported by previous studies providing
important insights into the molecular and cellular patho-
genesis of these tumors [2, 8, 17, 25]. Several pathways
have been described to be activated in adaCP cell clus-
ters with nuclear β-catenin accumulations, including the
Wnt pathway, the epidermal growth factor receptor
pathway and the sonic hedgehog pathway [1, 18, 20, 23,
24, 46]. A novel tumor stem cell niche (CD133 and
CD44), a specific cellular environment at the brain inva-
sion border (TNC and MAP2) and a novel role for pitu-
itary stem cells in the pathogenesis of adaCP has been
proposed [2, 8, 17, 25]. Using array-based gene expression
profiling we were able to confirm these associations in
terms of transcriptional differences. Comparing papCP
and adaCP tumor samples, the latter showed significant
up-regulation of direct targets of the Wnt/β-catenin sig-
naling pathway (LEF1 and AXIN2) as well as important
components of the hedgehog signaling pathway (GLI2,
PTCH1 and SHH). Furthermore, CLDN1 (a recently intro-
duced marker to differentiate between CP subtypes)
showed significantly higher expression levels in papCP
[47]. Detection of tumor-specific signaling pathway activa-
tion enables the possibility of target-oriented intervention.
Testing of novel pharmacological treatments for both CP
variants is on the way, and will hopefully provide add-
itional therapeutic options in the future, with BRAF
V600E inhibition being a particularly attractive approach.
Reports regarding epigenomic differences in CP are
missing so far. Therefore, we conducted DNA methyla-
tion profiling and were able to clearly distinguish the
groups of adaCP and papCP. This was confirmed by
gene expression analysis, demonstrating that the two
subtypes are clearly molecularly distinct on both the epi-
genetic and transcriptional level.
One small biopsy of a histologically challenging case
(pap11) was integrated in the analysis and grouped
clearly into the papCP cluster, highlighting the utility of
this approach for classification. It is of note, that differen-
tial methylation analysis revealed no significant difference
between adaCP in children and adults. However, differen-
tial methylation and gene expression analysis emphasize
an epigenetic impact on the Wnt- and Hedgehog signaling
in adaCP as a whole. Further studies are currently under-
way to verify and specifically analyse additional differen-
tially methylated genes and to correlate this data with
gene expression profiles and clinical data.
Conclusion
This study clearly supports the assumption that adaCP
and papCP are two distinct entities with different genetic
and epigenetic backgrounds. They can be clearly diagnosed
in most cases by using BRAF V600E and CTNNB1 muta-
tion analysis but also by their methylation profile.
Innovative approaches studying large and well charac-
terized tumor samples may help to further understand
the pathogenesis of both variants and may lead to find
new treatment strategies.
Additional files
Additional file 1: Figure S1. CP subtypes show significant differences
in their gene expression profiles. Affymetrix U133 Plus2.0 expression
array data (in log2 expression units) of eighteen adaCP and ten papCP
illustrated differentially expressed genes involved in Wnt- (LEF1 and
AXIN2), Hedgehog signaling (PTCH1, GLI2 and SHH), and stem cell
characteristics (TNC, MAP2, PROM1, CD44) as well as intercellular adhesion
(CLDN1). (JPG 390 kb)
Additional file 2: Table S1. Single Affymetrix U133 Plus2.0 expression
array data of all adaCP and papCP analysed, given in log2 expression
units. (DOC 22.6 kb)
Additional file 3: Figure S2. Pediatric and adult adaCP do not have
different methylation or gene expression signatures. Volcano plot (a)
showing the difference in median methylation of genes between
pediatric (n = 7) and adult (n = 10) adaCP samples on the x-axis and the –
log10 transformed p-values of the corresponding t-test results on the y-axis.
The volcano plot on the right hand side (b) shows the difference in mean
gene expression of genes between pediatric and adult adaCP samples on
the x-axis and corresponding –log10 transformed t-test p-values on
the y-axis. No gene was found to be significantly differentially methylated or
differentially expressed. (JPG 338 kb)
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